NX210 / Axoltis Pharma, Godfrin Life-Sci - LARVOL DELTA

SCO-Spondin-Derived Peptide NX210 Promotes Functional Recovery after Spinal Cord Injury in Mice. (PubMed, J Neurotrauma) - "NX210 treatment also increased myelin basic protein and reduced neuron/glial antigen 2 at the injury site 10 weeks post-injury while no significant effects were observed on lesion size, inflammation, and neuron survival. Overall, this study highlights a potential new therapeutic strategy to promote repair and decrease long-lasting functional impairments after SCI."

Journal • Preclinical • CNS Disorders • Inflammation • Orthopedics • Pain • MBP • SPON1

SCO-spondin-derived peptide NX210 rescues neurons from cerebral ischemia/reperfusion injury through modulating the Integrin-β1 mediated PI3K/Akt pathway. (PubMed, Int Immunopharmacol) - "Overall, our results indicated that NX210 prevents oxidative stress and neuronal apoptosis in cerebral I/R via upregulation of the Integrin-β1/PI3K/Akt signaling pathway. These results indicated that NX210 may be a promising therapeutic candidate for ischemic stroke."

Journal • Cardiovascular • CNS Disorders • Ischemic stroke • Reperfusion Injury • SPON1

Safety, Tolerability, Pharmacokinetics and Initial Pharmacodynamics of a Subcommissural Organ-Spondin-Derived Peptide: A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose First-in-Human Study. (PubMed, Neurol Ther) - "NX210 is safe and well tolerated and may exert beneficial effects on the central nervous system, particularly in terms of cognitive processing."

Clinical • Journal • P1 data • PK/PD data • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Pain • SPON1

SUBCOMMISSURAL ORGAN-SPONDIN-DERIVED PEPTIDE IMPROVES MOTOR FUNCTION AND PROLONGS SURVIVAL IN A MOUSE MODEL OF AMYOTROPHIC LATERAL SCLEROSIS (ADPD 2022) - "Aims: NX210 is an innovative drug candidate peptide with pleiotropic functions derived from the subcommissural organ (SCO)-spondin, a large glycoprotein that strongly contributes to neuronal development. NX210c represents a promising disease-modifying drug candidate for ALS. Indeed, it prolongs mouse survival and reduces motor deficits in the SOD1G93A mouse model. Spinal cords were collected at 16 weeks old to investigate the cellular mechanisms underlying the beneficial effects of NX210c on ALS disease progression/survival."

Preclinical • Amyotrophic Lateral Sclerosis • CNS Disorders • SPON1

[VIRTUAL] A randomized, placebo-controlled, double-blind, single ascending dose study to evaluate the safety, tolerability and pharmacokinetics of a subcommissural organ-spondin-derived peptide in healthy volunteers (CTAD 2021) - "NX210 is a new compound that improves cognitive functions in acute and chronic CNS animal models in comparison to Donepezil (Le Douce et al., Front. Five ascending doses (0.4mg/k up to 10mg/kg) of i.v administered NX210 were safe and well tolerated by 39 healthy subjects in this first-in-man study. PK and PD results suggested favorable, rapid and sustainable effects of NX210 via its metabolite, NX210c. Considering altogether the marked drug dose effect with plasma tryptophan and homocysteine, trends of plasma glutamate (decrease) and glutamine (increase), as well as the dose effect on EEG alpha bands, they provide preliminary and encouraging elements of NX210/NX210c effect on the CNS, in particular on cognitive functions improvement."

Clinical • PK/PD data • Alzheimer's Disease • CNS Disorders • Pain • SPON1